Viirused (bioloogilised)

[Mõnuagent 007]

Ei viitsi guugeldada, aga kellele ivermektiini patent kuulub, et talle umbes Westonsiga samaväärilist PR-kampaaniat tehakse?

[Pints]

Ei viitsi guugeldada, aga kellele ivermektiini patent kuulub, et talle umbes Westonsiga samaväärilist PR-kampaaniat tehakse?

Ivermectin was discovered in 1975 and came into medical use in 1981; William Campbell and Satoshi Ōmura won the 2015 Nobel Prize in Physiology or Medicine for its discovery and applications.

*Merck's patent on ivermectin expired in 1996, though it was extended.

Merck Statement on Ivermectin use During the COVID-19 Pandemic

-No scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies;
-No meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease, and;
-A concerning lack of safety data in the majority of studies.

[Mõnuagent 007]

Ivermectin was discovered in 1975 and came into medical use in 1981; William Campbell and Satoshi Ōmura won the 2015 Nobel Prize in Physiology or Medicine for its discovery and applications.

*Merck's patent on ivermectin expired in 1996, though it was extended.

Merck Statement on Ivermectin use During the COVID-19 Pandemic

-No scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies;
-No meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease, and;
-A concerning lack of safety data in the majority of studies.

No see on nagu Helme ei võitle vaktsineerimise vastu, vaid vaktsineerimisvabaduse eest! #vandenõu

[rahvaspordipäev]

Ivermectin was discovered in 1975 and came into medical use in 1981; William Campbell and Satoshi Ōmura won the 2015 Nobel Prize in Physiology or Medicine for its discovery and applications.

*Merck's patent on ivermectin expired in 1996, though it was extended.

Merck Statement on Ivermectin use During the COVID-19 Pandemic

-No scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies;
-No meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease, and;
-A concerning lack of safety data in the majority of studies.

Hobuseussiravimihindasid jälgides on lihtne vaadata siit kuidas nad kümnekordistusid äkki

[Pints]

Hobuseussiravimihindasid jälgides on lihtne vaadata siit kuidas nad kümnekordistusid äkki

Ulme!




Well played sir, well played!

[kaala]

Mtea ma küll leidsin kohe infot, et ei ole ainult persekukkunud ussirohi koeradele ja hobustele. Aga kütke edasi, Kui uudisejupis on Helme nimi siis järelikult on köik täispask millele tuleb vastu vöidelda

"The paper summarized the results of a clinical trial seeming to show that ivermectin can reduce COVID-19 death rates by more than 90%1 — among the largest studies of the drug’s ability to treat COVID-19 to date. But on 14 July, after internet sleuths raised concerns about plagiarism and data manipulation, the preprint server Research Square withdrew the paper because of “ethical concerns”.

Ahmed Elgazzar at Benha University in Egypt, who is one of the authors on the paper, told Nature he was not given a chance to defend his work before it was removed.

"Carlos Chaccour, a global-health researcher at the Barcelona Institute for Global Health in Spain, says it has been difficult to conduct rigorous studies on ivermectin. That’s partly because funders and academics in wealthy countries haven’t supported them, and, he suspects, have often dismissed trials of ivermectin because most of them have been done in lower-income countries. "

https://www.nature.com/articles/d41586-021-02081-w

Conclusions:
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin.

https://journals.lww.com/americantherapeutics/fulltext/2021/08000/ivermectin_for_prevention_and_treatment_of.7.aspx

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

https://pubmed.ncbi.nlm.nih.gov/32251768/

https://c19ivermectin.com/

Praktiliselt sama hea kui tuberkuloosiravimit covidi vastu vötta ju

[Pints]

Mtea ma küll leidsin kohe infot, et ei ole ainult persekukkunud ussirohi koeradele ja hobustele. Aga kütke edasi, Kui uudisejupis on Helme nimi siis järelikult on köik täispask millele tuleb vastu vöidelda

"The paper summarized the results of a clinical trial seeming to show that ivermectin can reduce COVID-19 death rates by more than 90%1 — among the largest studies of the drug’s ability to treat COVID-19 to date. But on 14 July, after internet sleuths raised concerns about plagiarism and data manipulation, the preprint server Research Square withdrew the paper because of “ethical concerns”.

Ahmed Elgazzar at Benha University in Egypt, who is one of the authors on the paper, told Nature he was not given a chance to defend his work before it was removed.

"Carlos Chaccour, a global-health researcher at the Barcelona Institute for Global Health in Spain, says it has been difficult to conduct rigorous studies on ivermectin. That’s partly because funders and academics in wealthy countries haven’t supported them, and, he suspects, have often dismissed trials of ivermectin because most of them have been done in lower-income countries. "

https://www.nature.com/articles/d41586-021-02081-w

Conclusions:
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin.

https://journals.lww.com/americantherapeutics/fulltext/2021/08000/ivermectin_for_prevention_and_treatment_of.7.aspx

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

https://pubmed.ncbi.nlm.nih.gov/32251768/

https://c19ivermectin.com/

Merck on siis kari lolle, kes tasuta raha ei soovi?

KENILWORTH, N.J., Feb. 4, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today affirmed its position regarding use of ivermectin during the COVID-19 pandemic. Company scientists continue to carefully examine the findings of all available and emerging studies of ivermectin for the treatment of COVID-19 for evidence of efficacy and safety. It is important to note that, to-date, our analysis has identified:

- No scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies;
- No meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease, and;
- A concerning lack of safety data in the majority of studies.

We do not believe that the data available support the safety and efficacy of ivermectin beyond the doses and populations indicated in the regulatory agency-approved prescribing information.

[kaala]

Merck on siis kari lolle, kes tasuta raha ei soovi?

KENILWORTH, N.J., Feb. 4, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today affirmed its position regarding use of ivermectin during the COVID-19 pandemic. Company scientists continue to carefully examine the findings of all available and emerging studies of ivermectin for the treatment of COVID-19 for evidence of efficacy and safety. It is important to note that, to-date, our analysis has identified:

- No scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies;
- No meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease, and;
- A concerning lack of safety data in the majority of studies.

We do not believe that the data available support the safety and efficacy of ivermectin beyond the doses and populations indicated in the regulatory agency-approved prescribing information.

Veebruaris kirjutasid? Enamus need trialid peale seda olnud ju. Küsimusele ei oska vastata. Kui sain kohe mitmelt poolt söimata, kui julgesin öelda, et see on ka inimeste ravim ja juba aastaid, siis see näitab lihtsalt et see on tugevalt poliitiliselt ja emotsionaalselt laetud teema

[Pints]

Veebruaris kirjutasid? Enamus need trialid peale seda olnud ju. Küsimusele ei oska vastata. Kui sain kohe mitmelt poolt söimata, kui julgesin öelda, et see on ka inimeste ravim ja juba aastaid, siis see näitab lihtsalt et see on tugevalt poliitiliselt ja emotsionaalselt laetud teema

Muidugi on see ka inimestele mõeldud, üks levinumaid parasiidiravimeid.
Merck siiani kontrollib kõiki teadustõid (ilmselt) aga see et nad pole pidanud vajalikuks uut statementi teha on üsna kõnekas.

[kaala]

Muidugi on see ka inimestele mõeldud, üks levinumaid parasiidiravimeid.
Merck siiani kontrollib kõiki teadustõid (ilmselt) aga see et nad pole pidanud vajalikuks uut statementi teha on üsna kõnekas.

Miks nad peaksidki? Mis meditsiinifirmat esmalt motiveeribki, raha vöi inimeste ravimine? Könekas on hoopis see, et nad just tulid välja 700 daalase (40x omahinnast) ravimiga, mille tulemused pole kuidagi paremad Ivermektiinist, mis maksab 29 daala. Milleks müüa juba töestatud ja odavat, kui saab teha uue ja 25x kallima.

https://theintercept.com/2021/10/05/covid-pill-drug-pricing-merck-ridgeback/

[Pints]

Miks nad peaksidki? Mis meditsiinifirmat esmalt motiveeribki, raha vöi inimeste ravimine? Könekas on hoopis see, et nad just tulid välja 700 daalase (40x omahinnast) ravimiga, mille tulemused pole kuidagi paremad Ivermektiinist, mis maksab 29 daala. Milleks müüa juba töestatud ja odavat, kui saab teha uue ja 25x kallima.


https://theintercept.com/2021/10/05/...rck-ridgeback/

Need "40 korda omahinnast kallimad" pealkirjad ei arvesta tihti tootearenduse ja investeeringutega. Molnupiraviri (katsed alles käivad) ja ivermectini ma võrrelda ei oska muidugi. FDA AdCom 30 november, eks siis kuuleb alles.

Dr. Stephen Griffin, virologist and associate professor at the University of Leeds (here), told Reuters that molnupiravir is not repackaged ivermectin.

The two drugs have “dissimilar chemistry,” he said. “There is no way that Merck is doing this,” he said.

“Molnupiravir is a derivative of a nucleotide that, predictably, interferes with the RNA replication of the virus. While Ivermectin does also have a defined mechanism of action, BUT it’s against ion channels found in parasites,” Griffin said.

[kaala]

Molnupiravir efektiivsus 50%, Ivermektiini trialite keskmine 67% . Ühele tehakse lihtsalt kövasti downplayd. Oleks see Ivermektiin ka tonnine drug oleks ammu load olemas ja sul söbrad sööksid esimesi tablette

[Pints]

Molnupiravir efektiivsus 50%, Ivermektiini trialite keskmine 67% . Ühele tehakse lihtsalt kövasti downplayd. Oleks see Ivermektiin ka tonnine drug oleks ammu load olemas ja sul söbrad sööksid esimesi tablette

Miks Merck peaks efektiivsust märgatavalt maha keerama?
Olgu mainitud, et oleks äge küll kui miskit töötavat valmis saadakse.

[vendetta]

Keegi Dark Waters vaatas õhtul? Todd Haynesi vist ekre või Trumpi käpikuks olemises süüdistada ei saa, nii et võib rääkida? See hirm, et suur korporatsioon miljardikasumite nimel tavainimesele kraevahele laseb, ei ole sugugi nii tühja koha pealt võetud. Samas huvitaval kombel oli selles õnnetus C8 juhtumis väga aktiivselt esindatud ka praeguse kriisiretsepti teine pool. Lääne inimesele hirmsasti meeldib mõelda, et on olemas üdini positiivne toode, mis lahendab mingi konkreetse probleemi nüüd ja igaveseks ajaks...

[Pints]

Keegi Dark Waters vaatas õhtul? Todd Haynesi vist ekre või Trumpi käpikuks olemises süüdistada ei saa, nii et võib rääkida? See hirm, et suur korporatsioon miljardikasumite nimel tavainimesele kraevahele laseb, ei ole sugugi nii tühja koha pealt võetud. Samas huvitaval kombel oli selles õnnetus C8 juhtumis väga aktiivselt esindatud ka praeguse kriisiretsepti teine pool. Lääne inimesele hirmsasti meeldib mõelda, et on olemas üdini positiivne toode, mis lahendab mingi konkreetse probleemi nüüd ja igaveseks ajaks...

Muidugi pole, isegi nähtud kuidas "meeleheite grupile" - nii neid ravimitööstuses nimetatakse (Sclerosis multiplex, RRMS, PPMS jne.) püütakse ebaõnnestunud ravimeid sokutada (mis algset haigust üldse ei ravi ja kus MS trialite success rate max 5% või sama mis platseebol), sest investeeringud juba tehtud - viskavad meie neuroloogidele pisikese nutsaka, viivad soojale maale koolitusele ning Haigekassa plekib nende kahjumi osaliselt kinni - seda korrata paarikümnes riigis ja äkki tiksub pisikene kasum isegi. Novartis toimetas vähemalt kunagi nii oma aeguvate või ebaõnnestunud patentidega, sest raskelt haige inimene on valmis kõike proovima.